Vaxcyte Announces Webcast to Share Study Results
Vaxcyte, Inc. (NASDAQ: PCVX), a leader in vaccine innovation, is thrilled to announce an upcoming webcast and conference call. This event will reveal the topline results from its Phase 1/2 study on VAX-31, a 31-valent pneumococcal conjugate vaccine aimed specifically at adults aged 50 and older. Mark your calendars for 8:00 a.m. Eastern Time.
What You Need to Know About VAX-31
VAX-31 is a promising candidate designed to fight invasive pneumococcal disease (IPD). The Phase 1/2 study is focused on assessing its safety, tolerability, and immunogenicity in healthy adults within the target age group. The goal is to position VAX-31 as a strong option for preventing infections caused by pneumococcal bacteria.
How to Access the Webcast
If you're interested in joining the conference call, you can dial 800-225-9448 for domestic calls or 203-518-9708 for international access. Don't forget to mention the conference ID PCVX0903 when you call in. Additionally, a live webcast will be available on Vaxcyte's investor relations webpage, providing a convenient option for those who prefer to attend online.
Replay Availability
For anyone unable to attend the live event, a replay will be accessible on the Vaxcyte website for 30 days after the presentation, ensuring that everyone can stay informed about this important information.
The Vision Behind Vaxcyte
Vaxcyte is dedicated to advancing high-fidelity vaccines that address bacterial diseases impacting global health. While VAX-31 is a key focus, the company is also progressing with VAX-24, a 24-valent vaccine that is ready to enter Phase 3 trials. This innovative strategy aims to provide broad coverage against multiple serotypes responsible for significant IPD, enhancing protection for both children and adults.
Leading the Way in Vaccine Development
Vaxcyte is at the cutting edge of vaccine technology, utilizing modern synthetic techniques such as the XpressCF™ cell-free protein synthesis platform. This method, exclusively licensed from Sutro Biopharma, enables the efficient production of complex proteins and antigens. This technological advantage is essential for creating effective, high-fidelity vaccines that can improve immunological outcomes.
Exploring Additional Vaccine Candidates
Beyond VAX-31 and VAX-24, Vaxcyte is actively developing a range of vaccine candidates targeting various bacterial infections. Noteworthy projects include VAX-A1, aimed at Group A Strep infections; VAX-PG, focused on periodontal disease; and VAX-GI, designed to prevent Shigella infections. Each candidate reflects Vaxcyte's commitment to addressing serious health challenges related to bacterial infections.
Contact Information
For any inquiries, please reach out to Patrick Ryan, Executive Director of Corporate Communications, at 415-606-5135. Media inquiries can be directed to media@vaxcyte.com, while investor relations can be contacted through Jennifer Zibuda at 860-729-8902 or via email at investors@vaxcyte.com.
Frequently Asked Questions
What is VAX-31?
VAX-31 is a 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease in adults aged 50 and older.
When is the webcast scheduled?
The webcast is scheduled for 8:00 a.m. Eastern Time on the day following the announcement.
How can I participate in the conference call?
To join the conference call, dial 800-225-9448 for domestic calls or 203-518-9708 for international calls, and use conference ID PCVX0903.
Will a replay be available?
Yes, a replay of the webcast will be accessible on the Vaxcyte website for 30 days after the event.
What other vaccines is Vaxcyte developing?
In addition to VAX-31 and VAX-24, Vaxcyte is also working on VAX-A1 for Group A Strep, VAX-PG for periodontal disease, and VAX-GI for preventing Shigella.
